The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma

Oncotarget

Volumn 7, Issue 4, 2016, Pages 4183-4194

  Wang, Lai Mun ^a   Silva, Michael A ^a   D'Costa, Zenobia ^b   Bockelmann, Robin ^b   Soonawalla, Zahir ^a   Liu, Stanley ^c   O'Neill, Eric ^b   Mukherjee, Somnath ^b   McKenna, W Gillies ^b   Muschel, Ruth ^b   Fokas, Emmanouil ^b  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Sunnybrook Health Sciences Centre   (Canada)

Author keywords

aSMA; Desmoplasia; Pancreatic cancer; Prognosis; Stroma density

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GEMCITABINE; ANTINEOPLASTIC AGENT;

ANALYTICAL PARAMETERS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DESMOPLASTIC STROMA; DISEASE ASSOCIATION; DISTANT METASTASIS FREE SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOCAL PROGRESSION FREE SURVIVAL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATIC STELLATE CELL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STROMA; STROMA DENSITY; SURVIVAL RATE; SURVIVAL TIME; VALIDATION PROCESS; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; LYMPH NODE METASTASIS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; STROMA CELL; TUMOR INVASION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; STROMAL CELLS; SURVIVAL RATE;

EID: 84958025726     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6770     Document Type: Article

References (43)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010; 362:1605-1617.
2. Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015; 6:4553-4561. doi:10.18632/oncotarget.2972.
3. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA. Stromal biology and therapy in pancreatic cancer. Gut. 2011; 60:861-868.
4. Fokas E, O'Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. Biochim Biophys Acta. 2015; 1855:61-82.
5. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324:1457-1461.
6. Mantoni TS, Lunardi S, Al-Assar O, Masamune A, Brunner TB. Pancreatic stellate cells radioprotect pancreatic cancer cells through β1-integrin signaling. Cancer Res. 2011; 71:3453-3458.
7. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21:418-429.
8. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25:719-734.
9. Sinn M, Denkert C, Striefler JK, Pelzer U, Stieler JM, Bahra M, Lohneis P, Dorken B, Oettle H, Riess H, Sinn BV. alpha-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. British journal of cancer. 2014; 111:1917-1923.
10. Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, Gomez I, Soldevilla B, Munoz C, Provencio M, Campos-Martin Y, Garcia de Herreros A, Casal I, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer science. 2013; 104:437-444.
11. Underwood TJ, Hayden AL, Derouet M, Garcia E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M, Uzoho C, Primrose JN, Blaydes JP, et al. Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. The Journal of pathology. 2015; 235: 466-477.
12. Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, Upile T, Kalavrezos N, Violette SM, Weinreb PH, Chester KA, Chana JS, Marshall JF, et al. Stromal features are predictive of disease mortality in oral cancer patients. The Journal of pathology. 2011; 223:470-481.
13. Erkan M, Michalski CW, Rieder S, Reiser-Erkan C, Abiatari I, Kolb A, Giese NA, Esposito I, Friess H, Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008; 6:1155-1161.
14. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn JG, Sleijfer S, Foekens JA, Berns EM. Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14:5555-5564.
15. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nature reviews Molecular cell biology. 2014; 15:786-801.
16. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25:735-747.
17. Gore J, Korc M. Pancreatic cancer stroma: friend or foe? Cancer cell. 2014; 25:711-712.
18. Ueno H, Jones AM, Wilkinson KH, Jass JR, Talbot IC. Histological categorisation of fibrotic cancer stroma in advanced rectal cancer. Gut. 2004; 53:581-586.
19. Ueno H, Konishi T, Ishikawa Y, Shimazaki H, Ueno M, Aosasa S, Saiura A, Hase K, Yamamoto J. Histologic categorization of fibrotic cancer stroma in the primary tumor is an independent prognostic index in resectable colorectal liver metastasis. The American journal of surgical pathology. 2014; 38:1380-1386.
20. Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB (Oxford). 2015; 17:292-298.
21. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, Friess H. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012; 9:454-467.
22. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. The American journal of surgical pathology. 2009; 33:134-141.
23. Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.). New Jersey: Lawrence Erlbaum.
24. Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch HJ, Hwang RF, Jaster R, Kleeff J, et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut. 2012; 61:172-178.
25. Erkan M, Reiser-Erkan C, Michalski CW, Deucker S, Sauliunaite D, Streit S, Esposito I, Friess H, Kleeff J. Cancer-stellate cell interactions perpetuate the hypoxiafibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009; 11:497-508.
26. Ikenaga N, Ohuchida K, Mizumoto K, Cui L, Kayashima T, Morimatsu K, Moriyama T, Nakata K, Fujita H, Tanaka M. CD10+ pancreatic stellate cells enhance the progression of pancreatic cancer. Gastroenterology. 2010; 139:1041-1051.
27. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB, Logsdon CD. Cancerassociated stromal fibroblasts promote pancreatic tumor progression. Cancer research. 2008; 68:918-926.
28. Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, Soylu E, Ghallab M, Bor D, Froeling FE, Bhattacharya S, Rustgi AK, Sahai E, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol. 2013; 230:107-117.
29. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology. 2011; 141:1486-1497, 1497 e1481-1414.
30. Fujita H, Ohuchida K, Mizumoto K, Nakata K, Yu J, Kayashima T, Cui L, Manabe T, Ohtsuka T, Tanaka M. alpha-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma. Pancreas. 2010 May 7; PMID: 20467342.
31. Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013; 258:336-346.
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
33. Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res. 2015; 3:1-11.
34. Erkan M. Understanding the stroma of pancreatic cancer: co-evolution of the microenvironment with epithelial carcinogenesis. The Journal of pathology. 2013; 231:4-7.
35. Erkan M, Hausmann S, Michalski CW, Schlitter AM, Fingerle AA, Dobritz M, Friess H, Kleeff J. How fibrosis influences imaging and surgical decisions in pancreatic cancer. Frontiers in physiology. 2012; 3:389.
36. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis. American journal of physiology Cell physiology. 2013; 304:C216-225.
37. Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Buchler MW, Werner J. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Annals of surgery. 2011; 254:311-319.
38. Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, Tomlinson JS. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010; 17:2312-2320.
39. Nakanishi H, Oguri K, Takenaga K, Hosoda S, Okayama M. Differential fibrotic stromal responses of host tissue to lowand high-metastatic cloned Lewis lung carcinoma cells. Lab Invest. 1994; 70:324-332.
40. Lunevicius R, Nakanishi H, Ito S, Kozaki K, Kato T, Tatematsu M, Yasui K. Clinicopathological significance of fibrotic capsule formation around liver metastasis from colorectal cancer. Journal of cancer research and clinical oncology. 2001; 127:193-199.
41. Galvan JA, Zlobec I, Wartenberg M, Lugli A, Gloor B, Perren A, Karamitopoulou E. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. British journal of cancer. 2015; 112:1944-1950.
42. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 2013; 19:1410-1422.
43. Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015; 64:1476-1484.